AGP Executive Report
Last update: 7 hours agoHepatitis B Vaccine Trial: A controversial study in Guinea-Bissau has won approval from the University of Southern Denmark and local officials, despite months of international criticism. Researchers plan to enroll 14,000 newborns, giving half the hepatitis B vaccine at birth and delaying it for six weeks for the rest. The disease affects nearly one in five people in the country, and experts warn that delaying the proven vaccine could leave babies vulnerable to lifelong infection. U.S. Funding: The CDC is reportedly preparing $1.6 million for the trial, which had been suspended earlier this year. Health advocates say the design raises serious ethical concerns.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
